United States Patent 8,895,615: Claim Scope, Exclusivity, Orange Book Position and Generic Risk

US Patent 8,895,615 protects a once-daily, extended-release amantadine treatment method for Parkinson’s disease, particularly dyskinesia and levodopa-induced dyskinesia. Its central limitation is pharmacokinetic: the extended-release dose must reduce the early post-dose amantadine concentration slope to less than 40% of the slope produced by an equivalent immediate-release dose. The patent therefore reaches beyond a named product and can cover different extended-release formulations if they satisfy the claimed dose, use, and pharmacokinetic profile.

The patent is method-of-treatment protection, not a broad composition-of-matter patent. Its practical value depends on whether a generic or competing product is administered once daily to Parkinson’s patients at the claimed dose and produces the specified pharmacokinetic result.

What does US Patent 8,895,615 protect?

The independent claims require all of the following:

Limitation	Required scope
Patient	Human subject with Parkinson’s disease
Route	Oral administration
Frequency	Once daily
Dose	200 mg to 500 mg of amantadine or a pharmaceutically acceptable salt
Formulation	At least 50% of the drug in extended-release form
Excipients	At least one excipient
Pharmacokinetics	Early amantadine plasma concentration slope, dC/dT, below 40% of the equivalent immediate-release comparator
Study design	Single-dose human pharmacokinetic study
Claims 1-3	Different measurement intervals for the dC/dT comparison

The patent does not require a particular tablet shape, coating, polymer, osmotic mechanism, excipient, brand name, or manufacturing process in claims 1-3. A product can fall within the independent claims if it uses a different extended-release technology and satisfies the claimed pharmacokinetic result.

The claims also cover amantadine salts. A product containing amantadine hydrochloride would generally fall within the claimed drug category if the other limitations are met.

How do claims 1, 2 and 3 differ?

The principal distinction is the time interval used to calculate the concentration slope.

Claim	Extended-release dC/dT interval	Immediate-release comparator interval
1	0 to 4 hours after administration	0 to 4 hours after administration
2	Administration to the immediate-release Tmax	Same corresponding immediate-release Tmax period
3	2 to 4 hours after administration	Administration to immediate-release Tmax

Claims 1 and 2 compare early exposure over intervals beginning at administration. Claim 3 is different because it measures the extended-release dose between two and four hours, while measuring the immediate-release comparator from administration through its Tmax.

This structure creates several infringement questions:

The accused product must be compared with the same quantity of amantadine in immediate-release form.
The comparison must use a single-dose human pharmacokinetic study.
The relevant dC/dT must be calculated over the claim-specific period.
“Less than 40%” is a strict threshold. A result equal to 40% would not literally satisfy that numerical limitation.
The patent requires a mean result, not necessarily that every individual subject fall below the threshold.

The claims do not expressly require a particular absolute plasma concentration, Cmax, area under the curve, or terminal half-life. The key metric is the early concentration-time slope.

What do the dependent claims add?

Claims 4 through 16 narrow or supplement the independent method claims.

Claim	Added limitation	Commercial significance
4	Dose of 300 mg to 500 mg	Captures higher-dose once-daily regimens
5	At least 75% extended-release drug	Narrows the formulation mix
6	Extended-release and immediate-release drug in the same dose	Covers combination release profiles
7	At least 90% extended-release drug	Approaches an almost entirely extended-release product
8	Therapeutically effective Parkinson’s treatment	Adds an efficacy requirement
9	Patient suffers from dyskinesia	Narrows the disease population
10	Reduced dyskinesia frequency or severity	Adds a clinical outcome
11	Levodopa-induced dyskinesia	Targets the principal commercial use
12	Concurrent levodopa/carbidopa administration	Covers adjunctive treatment
13	Tmax shift of 2 to 16 hours	Adds a second pharmacokinetic limitation
14	Osmotic device	Protects a specific release mechanism
15	Maintained extent of bioavailability	Requires preservation of overall exposure
16	Therapeutically effective from onset of therapy	Addresses initial treatment use

Claims 9-12 are commercially important because they connect the formulation to dyskinesia treatment, especially levodopa-induced dyskinesia. Claim 14 is technically narrower than the other dependent claims because it requires an osmotic device using osmotic driving force.

Claim 6 is significant for hybrid formulations. A product containing both immediate-release and extended-release amantadine can remain within the estate if the total dose and pharmacokinetic slope satisfy the claim. Claims 5 and 7 impose percentage thresholds that may distinguish a substantially extended-release product from a mixed-release formulation.

What formulations are protected by US 8,895,615?

The patent can cover several formulation categories:

A tablet containing at least 50% extended-release amantadine.
A capsule containing extended-release beads or multiparticulates.
An osmotic-release tablet.
A formulation combining immediate-release and extended-release amantadine.
A product using a different polymer, coating, membrane, pore former, or release-control mechanism from the original commercial product.
A formulation that maintains bioavailability while shifting Tmax and reducing early concentration increase.

The independent claims are performance-based. The formulation does not need to disclose or use the same excipients as the patented development candidate. A non-infringing design would therefore need to avoid at least one required limitation, such as:

dosing more than once daily;
using less than 200 mg or more than 500 mg;
administering less than 50% of the drug in extended-release form;
treating a patient without Parkinson’s disease;
failing the dC/dT threshold;
using a release profile that does not meet the relevant claim interval.

A formulation change alone may not avoid infringement if the new product still satisfies the claimed pharmacokinetic result.

Does the patent protect Gocovri?

Gocovri is amantadine extended-release capsules approved by the FDA for dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medication. The product uses a once-daily regimen and is commercially aligned with the subject matter of the patent. [2]

The claims supplied are broad enough to read on the core clinical concept behind Gocovri: once-daily extended-release amantadine for Parkinson’s disease with delayed and flattened early exposure. The patent should not be treated as covering every aspect of Gocovri, however. A product may be protected by several distinct patents covering formulation architecture, release technology, dosing, pharmacokinetics, or clinical use.

Patent 8,895,615 does not, based on the supplied claims alone, establish exclusive rights over:

the amantadine molecule itself;
all amantadine formulations;
all treatment of Parkinson’s disease;
all treatment of dyskinesia;
all once-daily amantadine dosing without the stated PK limitation;
the commercial product’s complete formulation or manufacturing process.

When does US Patent 8,895,615 lose exclusivity?

A US utility patent generally expires 20 years from the earliest effective nonprovisional priority date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments. [3]

The issue date of US 8,895,615 is November 25, 2014. The precise expiration date must be determined from the patent’s continuity data, PTA certificate, terminal-disclaimer status, and the USPTO patent-term calculation. The patent number and claims alone do not establish the final enforceable expiration date.

The relevant commercial date is not necessarily the patent’s expiration date. Generic entry may occur earlier through:

a Paragraph IV certification;
a settlement agreement;
a court judgment of invalidity or noninfringement;
a covenant not to sue;
a negotiated launch license;
expiration or delisting of a relevant Orange Book patent;
an authorized generic arrangement.

Any exclusivity analysis should therefore separate:

Exclusivity category	Relevance
Patent term	Statutory enforceability of the patent
FDA NCE exclusivity	Regulatory restriction on certain ANDA submissions
Orphan-drug exclusivity	Applies only if the approved indication has orphan designation
Pediatric exclusivity	Can add six months to applicable exclusivity or patent periods
Orange Book listing	Determines whether an ANDA applicant must address the patent
Litigation stay	Can delay FDA approval after a Paragraph IV notice

What is the Orange Book status of US 8,895,615?

The Orange Book is the controlling FDA source for patents submitted by an NDA holder and listed against an approved drug. FDA listing is product-specific. A patent may be relevant to a product’s commercial protection without every claim being listed, and an issued patent does not automatically create an Orange Book listing. [1]

For an Orange Book-listed patent, an ANDA applicant generally must provide a certification under 21 U.S.C. § 355(j)(2)(A)(vii). The relevant options are:

Paragraph I: no patent information has been submitted;
Paragraph II: the patent has expired;
Paragraph III: the applicant will wait until patent expiration;
Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.

The business effect of US 8,895,615 depends on whether it is currently listed against the relevant amantadine extended-release product, whether the listing remains operative, and whether the patent’s use claims correspond to the proposed ANDA labeling. These facts require the current FDA Orange Book listing and patent-term records, not the claim text alone.

What generic entry risks exist?

A generic applicant seeking approval of an amantadine extended-release product would face several possible pathways.

Paragraph IV challenge

A Paragraph IV applicant could argue that the patent is invalid, not infringed, or unenforceable. Likely technical positions would include:

the proposed formulation does not produce a dC/dT below 40%;
the relevant PK result cannot be established using the required comparator;
the study does not meet the single-dose human PK requirements;
the product does not contain at least 50% extended-release drug;
the proposed dosing regimen is not once daily;
the proposed label does not direct treatment of Parkinson’s disease;
the claims are anticipated or obvious over earlier amantadine extended-release disclosures;
the PK threshold is indefinite or lacks adequate written description or enablement.

Label-based design-around

A generic applicant could attempt to omit or carve out the patented dyskinesia indication. That strategy is difficult where the relevant claims require treatment of Parkinson’s disease but the product’s proposed labeling, physician use, or promotional conduct supports the patented use.

A skinny-label strategy is strongest when the patented use can be cleanly separated from unpatented uses and the remaining label does not encourage the patented method. It is weaker where the product’s principal or foreseeable use is the patented dyskinesia treatment.

PK design-around

A product might avoid the claims by using a release profile that does not reduce the early dC/dT below 40%. That approach creates a clinical and regulatory tradeoff. A slower or different release profile may avoid the patent but could produce a different Cmax, Tmax, exposure pattern, tolerability profile, or efficacy result.

Dose or frequency design-around

A twice-daily product, or a product outside the 200-500 mg range, would not literally meet the independent claims. Such a product would require a different development strategy and could face separate patents covering alternative dosing or formulation approaches.

How strong is the patent estate?

US 8,895,615 has meaningful claim breadth because its independent claims combine a broad active ingredient class with functional PK limitations. The claims are narrower than a composition patent but potentially broader than a formulation claim limited to named excipients or a specific manufacturing process.

Strength factor	Assessment
Active ingredient scope	Broad within amantadine and its acceptable salts
Dose scope	Broad 200-500 mg range
Disease scope	Limited to Parkinson’s disease in the independent claims
Release scope	Broad, at least 50% extended release
Technology scope	Not limited to a named release mechanism in claims 1-3
PK limitation	Potentially difficult to design around if clinical performance is similar
Proof burden	High, because infringement may require technical PK evidence
Method-claim limitation	Requires administration to a qualifying patient
Dependent-claim value	Stronger commercial focus on dyskinesia and levodopa-induced dyskinesia
Invalidity exposure	Depends on prior-art disclosure of dose, release profile, and PK relationship

The main enforcement advantage is that the claims do not depend solely on a particular brand or formulation recipe. The main weakness is proof. A patent owner may need access to clinical or bioequivalence data to establish the dC/dT relationship for an accused product.

What patent litigation affects amantadine extended-release products?

Patent litigation risk would most likely arise from an ANDA Paragraph IV notice directed to the relevant Orange Book patents. A patent owner could assert the listed patent under 35 U.S.C. § 271(e)(2), creating a statutory infringement action before commercial launch. A timely suit can trigger the statutory FDA approval stay described in 21 U.S.C. § 355(j)(5)(B)(iii). [4]

The principal litigation issues would likely include:

Claim construction of “mean change in amantadine plasma concentration as a function of time.”
The meaning of “same quantity” of drug in the immediate-release comparator.
Selection of the immediate-release Tmax.
Whether the dC/dT calculation must use subject-level data or pooled mean concentration data.
Whether an ANDA applicant’s proposed labeling induces administration for Parkinson’s disease or dyskinesia.
Whether the patent claims are enabled across the full 200-500 mg dose range.
Whether earlier amantadine products disclose the claimed PK relationship.

A formulation patent and a method patent may produce separate infringement theories. A generic applicant can avoid one patent while remaining exposed to another.

Which companies are relevant to the competitive landscape?

The commercial reference product is Gocovri, originally developed and commercialized by Adamas Pharmaceuticals. Adamas was acquired by Supernus Pharmaceuticals in 2021, making Supernus the relevant commercial successor for Gocovri-related assets and operations. [5]

The competitive landscape includes:

branded extended-release amantadine;
immediate-release amantadine products used off label or under older Parkinson’s regimens;
potential ANDA applicants for amantadine extended-release capsules;
alternative treatments for Parkinson’s disease and levodopa-induced dyskinesia;
future formulations using different release mechanisms or dosing schedules.

Biosimilar risk is not applicable. Amantadine is a small-molecule drug, and a competing product would ordinarily proceed through the generic drug pathway under section 505(j), not the biosimilar pathway under section 351(k). [6]

What revenue exposure does the patent create?

The patent’s commercial exposure is concentrated in once-daily extended-release amantadine used for Parkinson’s disease and dyskinesia. It does not protect all amantadine revenue. Immediate-release amantadine products, non-Parkinson’s uses, and formulations outside the claimed PK profile may fall outside the claims.

The highest-value exposure would arise if:

the patent is listed against the reference product;
the claims remain enforceable through the expected generic filing period;
the reference product’s principal indication overlaps the claimed Parkinson’s and dyskinesia uses;
the product’s commercial PK profile is difficult to design around;
the patent is one of several blocking patents requiring a coordinated challenge.

Revenue erosion would depend on the number of approved ANDAs, settlement terms, generic launch dates, authorized generic arrangements, and the presence of other surviving patents.

How does US 8,895,615 compare with a typical formulation patent?

Issue	US 8,895,615	Conventional formulation patent
Claim type	Method of treatment	Composition or formulation
Core limitation	Dose, use, release percentage, PK result	Ingredients, structure, manufacturing steps
Infringement proof	Patient use and PK performance	Product testing and formulation analysis
Design-around	Change dosing, use, release profile, or PK	Change ingredients or structure
Dependence on labeling	Often substantial	Usually lower
Coverage of alternative technology	Potentially broad	Often limited to claimed formulation
Generic challenge	Paragraph IV and use/PK defenses	Paragraph IV and product-composition defenses

The patent is strongest when a competing product reproduces the same clinical release profile. It is less useful against products that provide Parkinson’s treatment through a materially different dosing frequency or pharmacokinetic design.

Key Takeaways

US 8,895,615 covers once-daily oral administration of 200-500 mg amantadine or an acceptable salt to Parkinson’s patients.
At least 50% of the dose must be extended release.
The central limitation is an early dC/dT below 40% of an equivalent immediate-release dose.
Dependent claims target 300-500 mg doses, dyskinesia, levodopa-induced dyskinesia, levodopa/carbidopa coadministration, Tmax delay, osmotic delivery, and maintained bioavailability.
The patent is method-of-treatment protection, not composition-of-matter protection.
Biosimilar law is irrelevant; generic competition would proceed through the ANDA pathway.
A Paragraph IV challenge would likely focus on PK testing, claim construction, enablement, obviousness, and label-based infringement.
The enforceable expiration date and current Orange Book position must be determined from the USPTO and FDA records applicable to the relevant reference product.
Gocovri is the principal commercial product aligned with the claimed once-daily extended-release amantadine treatment concept.

FAQs

Can a generic avoid US 8,895,615 by using a different polymer?

Not necessarily. The independent claims are not limited to a particular polymer or excipient. A different polymer may still infringe if the product is administered once daily at 200-500 mg, contains at least 50% extended-release amantadine, treats Parkinson’s disease, and meets the claimed dC/dT relationship.

Does a 500 mg amantadine dose fall within the claims?

Yes. Claims 1-3 expressly cover 200 mg to 500 mg. Claim 4 separately covers 300 mg to 500 mg.

Does immediate-release amantadine alone infringe the patent?

Generally, not under the supplied claims. The claims require that at least 50% of the drug in the once-daily dose be in extended-release form.

Can a product avoid the patent by changing the dosing frequency to twice daily?

A twice-daily regimen would not literally satisfy the once-daily limitation. Other patents, labeling theories, or induced-infringement issues could still be relevant, but they are outside the supplied claim language.

Is an osmotic tablet required?

No. The osmotic-device limitation appears only in claim 14. Claims 1-13 and 15-16 do not require an osmotic delivery system.

References

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2018). Gocovri prescribing information.
United States Patent and Trademark Office. (n.d.). Patent term calculator.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
Supernus Pharmaceuticals, Inc. (2021). Supernus completes acquisition of Adamas Pharmaceuticals.
U.S. Food and Drug Administration. (n.d.). Biosimilar and interchangeable products.
United States Patent No. 8,895,615. (2014). Methods of treating Parkinson’s disease using extended-release amantadine.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2588296	⤷ Start Trial
European Patent Office	1845968	⤷ Start Trial
European Patent Office	2623099	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2006058236	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,895,615

Summary for Patent: 8,895,615